PMID- 31027517
OWN - NLM
STAT- MEDLINE
DCOM- 20190814
LR  - 20240402
IS  - 2047-783X (Electronic)
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 24
IP  - 1
DP  - 2019 Apr 26
TI  - Protective functions of myricetin in LPS-induced cardiomyocytes H9c2 cells injury 
      by regulation of MALAT1.
PG  - 20
LID - 10.1186/s40001-019-0378-5 [doi]
LID - 20
AB  - BACKGROUND: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a 
      crucial mediator in response to inflammation. Myricetin protects cardiomyocytes 
      against inflammatory injury. However, it's still unexplored whether myricetin 
      exerted anti-inflammatory properties via MALAT1. The purpose of our study was to 
      validate the cardio-protective function of myricetin against myocarditis and its 
      underlying mechanism in vitro. METHODS: H9c2 cells were pre-incubated with 
      myricetin before stimulation with lipopolysaccharide (LPS). Enforced silence of 
      MALAT1 was achieved by transducing short hairpin (sh)-MALAT1 into H9c2 cells. 
      Next, cell viability and apoptotic cells were detected with cell counting kit-8 
      (CCK-8) and Annexin V-fluorescein isothiocyanate/propidium iodide (Annexin 
      V-FITC/PI) apoptosis detection kit, respectively. Western blot assay was 
      conducted to examine apoptosis-relative proteins, pro-inflammatory factors, and 
      signaling regulators. Quantitative real-time PCR (qRT-PCR) was performed to 
      quantify pro-inflammatory factors and MALAT1 at mRNA levels. Enzyme-linked immune 
      sorbent assay (ELISA) was employed to determine protein concentration of 
      pro-inflammatory factors. RESULTS: Myricetin ameliorated LPS-elicited reduction 
      of cell viability, augment of apoptosis, and overexpression of monocyte 
      chemo-attractant protein-1 (MCP-1) and interleukin-6 (IL-6) in H9c2 cells. 
      Meanwhile, phosphorylation of p65 and inhibitor of nuclear factor kappa B alpha 
      (IkappaBalpha) were suppressed. Besides, myricetin enhanced the expression of MALAT1 
      which was originally down-regulated by LPS. However, the protective effects of 
      myricetin against LPS-caused inflammatory lesions were abrogated in 
      MALAT1-deficiency cells, with the restored phosphorylation of p65 and IkappaBalpha. 
      CONCLUSION: Myricetin possessed an anti-inflammatory function against LPS-induced 
      lesions in cardiomyocytes. Mechanically, myricetin up-regulated MALAT1, blocked 
      LPS-evoked activation of nuclear factor-kappaB (NF-kappaB) inflammatory pathway, and, 
      finally, exerted cardio-protective effects.
FAU - Sun, Jinliang
AU  - Sun J
AD  - Department of Cardiology, The First People's Hospital of Changzhou, No. 185 
      Juqian Street, Changzhou, 213000, China. sunjinliang0055@sina.com.
FAU - Sun, Jianhui
AU  - Sun J
AD  - Department of Cardiology, The First People's Hospital of Changzhou, No. 185 
      Juqian Street, Changzhou, 213000, China.
FAU - Zhou, Xuezhong
AU  - Zhou X
AD  - Department of Cardiology, The First People's Hospital of Changzhou, No. 185 
      Juqian Street, Changzhou, 213000, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20190426
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Flavonoids)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (MALAT1 long noncoding RNA, rat)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Long Noncoding)
RN  - 76XC01FTOJ (myricetin)
RIN - Eur J Med Res. 2024 Apr 1;29(1):212. PMID: 38561857
MH  - Animals
MH  - Cardiotonic Agents/*pharmacology
MH  - Cell Line
MH  - Flavonoids/chemistry/*pharmacology
MH  - Inflammation/pathology
MH  - Inflammation Mediators/metabolism
MH  - Lipopolysaccharides
MH  - Myocytes, Cardiac/drug effects/*metabolism/*pathology
MH  - NF-kappa B/metabolism
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Rats
MH  - Signal Transduction/drug effects
MH  - Up-Regulation/drug effects/genetics
PMC - PMC6485133
OTO - NOTNLM
OT  - Anti-inflammation
OT  - MALAT1
OT  - Myricetin
OT  - NF-kappaB
COIS- The authors declare that they have no competing interests.
EDAT- 2019/04/28 06:00
MHDA- 2019/08/15 06:00
PMCR- 2019/04/26
CRDT- 2019/04/28 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2019/04/10 00:00 [accepted]
PHST- 2019/04/28 06:00 [entrez]
PHST- 2019/04/28 06:00 [pubmed]
PHST- 2019/08/15 06:00 [medline]
PHST- 2019/04/26 00:00 [pmc-release]
AID - 10.1186/s40001-019-0378-5 [pii]
AID - 378 [pii]
AID - 10.1186/s40001-019-0378-5 [doi]
PST - epublish
SO  - Eur J Med Res. 2019 Apr 26;24(1):20. doi: 10.1186/s40001-019-0378-5.